FinscoFinsco

Arcturus Therapeutics (US.ARCT)

Capital Allocation Audit · Period: 2011 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ARCT · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion100.0%→
ROE-29.5%↓
Cash Conversion-→
D/E Ratio0.13↓
Gross Margin0.0%↓
US.ARCT (Arcturus Therapeutics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE              -29.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.13    ↓
Gross Margin       0.0%    ↓
Key Metrics
US.ARCT (Arcturus Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE -29.5% ↓
Cash Conversion - →
D/E Ratio 0.13 ↓
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies